Cargando…

Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers

Rosiglitazone (rosi) is a powerful insulin sensitizer, but serious toxicities have curtailed its widespread clinical use. Rosi functions as a high-affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ), the adipocyte-predominant nuclear receptor (NR). The classic model, involving b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Step, Sonia E., Lim, Hee-Woong, Marinis, Jill M., Prokesch, Andreas, Steger, David J., You, Seo-Hee, Won, Kyoung-Jae, Lazar, Mitchell A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory Press 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018489/ https://www.ncbi.nlm.nih.gov/pubmed/24788520 http://dx.doi.org/10.1101/gad.237628.114

Ejemplares similares

Rosiglitazone activation of PPARγ suppresses fractalkine signaling
por: Wan, Yihong, et al.
Publicado: (2010)

Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
por: Cellai, I, et al.
Publicado: (2006)

Genomic redistribution of GR monomers and dimers mediates transcriptional response to exogenous glucocorticoid in vivo
por: Lim, Hee-Woong, et al.
Publicado: (2015)

The PPARγ Agonist Rosiglitazone Impairs Colonic Inflammation in Mice with Experimental Colitis
por: Ramakers, Julian D., et al.
Publicado: (2007)

The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells
por: Wang, Zhenyu, et al.
Publicado: (2020)

The effects of PPARγ agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model
por: Guzeloglu, Mehmet, et al.
Publicado: (2012)

Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone
por: Cheng, Wing Yin, et al.
Publicado: (2016)

Electroacupuncture Reduces Weight Gain Induced by Rosiglitazone through PPARγ and Leptin Receptor in CNS
por: Jing, Xinyue, et al.
Publicado: (2016)

Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
por: Wang, Xue-Jiao, et al.
Publicado: (2014)

Expression of GPR43 in Brown Adipogenesis Is Enhanced by Rosiglitazone and Controlled by PPARγ/RXR Heterodimerization
por: Hu, Jiamiao, et al.
Publicado: (2018)

What is the impact of PPAR-γ agonist-rosiglitazone on ovarian reserve after hysterectomy? An experimental study
por: GÜNDOĞDU, Burcu, et al.
Publicado: (2020)

Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
por: Wu, Yanqiao, et al.
Publicado: (2020)

Rosiglitazone-Mediated Activation of PPARγ Restores HO1 Expression in the Human Preeclamptic Placenta
por: Grimaldi, Brooke, et al.
Publicado: (2023)

Expression of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ in the lung tissue of obese mice and the effect of rosiglitazone on proinflammatory cytokine expressions in the lung tissue
por: Ryu, Seung Lok, et al.
Publicado: (2013)

The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
por: Bogatkevich, Galina S., et al.
Publicado: (2012)

Activation of PPARγ by Rosiglitazone Does Not Negatively Impact Male Sex Steroid Hormones in Diabetic Rats
por: Mansour, Mahmoud, et al.
Publicado: (2009)

Retraction of “Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis”
por: Wu, Yanqiao, et al.
Publicado: (2021)

PPARγ is a nexus controlling alternative activation of macrophages via glutamine metabolism
por: Nelson, Victoria L., et al.
Publicado: (2018)

Shockwaves Suppress Adipocyte Differentiation via Decrease in PPARγ
por: Cho, Wonkyoung, et al.
Publicado: (2020)

Isoform-specific functions of PPARγ in gene regulation and metabolism
por: Hu, Wenxiang, et al.
Publicado: (2022)

Influence of Rosiglitazone on the Expression of PPARγ, NF-κB, and TNF-α in Rat Model of Ulcerative Colitis
por: Mao, Jing-Wei, et al.
Publicado: (2012)

Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver
por: Lee, Samuel M., et al.
Publicado: (2021)

Thiazolidinediones on PPARγ: The Roles in Bone Remodeling
por: Wei, Wei, et al.
Publicado: (2011)

Rosiglitazone Restores Endothelial Dysfunction in a Rat Model of Metabolic Syndrome through PPARγ- and PPARδ-Dependent Phosphorylation of Akt and eNOS
por: Zhao, Zhigang, et al.
Publicado: (2011)

Regulation of Chemokine and Chemokine Receptor Expression by PPARγ in Adipocytes and Macrophages
por: Nguyen, M. T. Audrey, et al.
Publicado: (2012)

Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist
por: Goto, Tsuyoshi, et al.
Publicado: (2011)

Identification of Regulatory Elements That Control PPARγ Expression in Adipocyte Progenitors
por: Chou, Wen-Ling, et al.
Publicado: (2013)

PPARγ Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice
por: Sun, Ying, et al.
Publicado: (2013)

Rosiglitazone via PPARγ-dependent suppression of oxidative stress attenuates endothelial dysfunction in rats fed homocysteine thiolactone
por: Yang, Xu-Hong, et al.
Publicado: (2015)

Rosiglitazone suppresses RANKL‐induced NFATc1 autoamplification by disrupting the physical interaction between NFATc1 and PPARγ
por: Park, Kyeong‐Lok, et al.
Publicado: (2018)

Rosiglitazone, a Ligand to PPARγ, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation
por: Sánchez-Aguilar, María, et al.
Publicado: (2019)

Rosiglitazone Alleviates Contrast-Induced Acute Kidney Injury in Rats via the PPARγ/NLRP3 Signaling Pathway
por: Wu, Jiayi, et al.
Publicado: (2022)

Impact of Targeted PPARγ Disruption on Bone Remodeling
por: Cao, Jay, et al.
Publicado: (2015)

The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone, ameliorates neurofunctional and neuroinflammatory abnormalities in a rat model of Gulf War Illness
por: Keledjian, Kaspar, et al.
Publicado: (2020)

Coprinus comatus Cap Inhibits Adipocyte Differentiation via Regulation of PPARγ and Akt Signaling Pathway
por: Park, Hyoung Joon, et al.
Publicado: (2014)

Enhancement of select cognitive domains with rosiglitazone implicates dorsal hippocampus circuitry sensitive to PPARγ agonism in an Alzheimer's mouse model
por: Cortez, IbDanelo, et al.
Publicado: (2020)

Retracted: Rosiglitazone Alleviates Contrast-Induced Acute Kidney Injury in Rats via the PPARγ/NLRP3 Signaling Pathway
por: Markers, Disease
Publicado: (2023)

A Novel Splicing Variant of Peroxisome Proliferator-Activated Receptor-γ (Pparγ1sv) Cooperatively Regulates Adipocyte Differentiation with Pparγ2
por: Takenaka, Yasuhiro, et al.
Publicado: (2013)

Nuclear Receptor Cofactors in PPARγ-Mediated Adipogenesis and Adipocyte Energy Metabolism
por: Powell, Emily, et al.
Publicado: (2007)

The small molecule phenamil is a modulator of adipocyte differentiation and PPARγ expression
por: Won Park, Kye, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5moncd91dtoedhj9fi4uhauo9o